Fate Therapeutics Announces Leadership Transition
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025Scott Wolchko To Retire as President and CEO after 10 years of Leadership in ...
Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.